EMA assesses active substance safety

Published: 15-Apr-2013
Regulatory

For nationally approved medicines


The European Medicines Agency (EMA) is expanding its retroactive safety reviews of active substances in medicines legally sold in the European Union (EU).

Until now EMA only assessed those substances with EU-wide market approvals. Next year it will assess substances in medicines with approvals from more than one EU national regulator, but no pan-EU sales rights.

See more

You may also like

Regulatory

EMA issues positive opinion on Calliditas' orphan drug

Read more
Calliditas' application for orphan drug designation in the European Union (EU) for setanaxib in Alport syndrome has received a positive opinion from European Medicines Agency

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.
    NICE approval is not enough: why the UK’s next medicines challenge is operational delivery A medicine is not truly accessible until it can be manufactured, procured, stocked, prescribed, dispensed and delivered reliably. That distinction is becoming increasingly important, says Varun Cruz, founder of NEUVIOR
  2. Bruker announces major strides in 4D proteomics performance, further advances In intact and top-down functional proteoform analysis, and innovations in hybrid qual/quant 4D metabolomics All to enable deeper insights into disease biology. Bruker Also Launches Two Novel Mass Spectrometry Systems for Unique Applications in Energy Industry Research, and in Semiconductor Manufacturing
  3. FDA Form 483 flags falsified records and live bird infestation at Dabur India OTC plant A FDA inspection report issued in January 2026 has revealed widespread CGMP failures at Dabur India's Dadra and Nagar Haveli facility, including manipulated microbiology data, fraudulent equipment logs and unsanitary storage conditions
  4. Lonza and Oxford Nanopore launch direct RNA sequencing solution for GMP mRNA quality control New nanopore sequencing and machine learning workflow simplifies multi-attribute QC testing for mRNA therapeutics
  5. Safety in pharmaceutical manufacturing: why a trusted partner makes all the difference By taking a three-tiered approach to protecting patients and personnel and ensuring plant compliance, GEA adopts a consultative approach to helping its customers navigate the responsibilities of pharmaceutical manufacturing safety with confidence

Upcoming event

BIO International Convention

22–25 June 2026 | Convention | Boston, US See all

You may also like

Regulatory

EMA issues positive opinion on Calliditas' orphan drug

Calliditas' application for orphan drug designation in the European Union (EU) for setanaxib in Alport syndrome has received a positive opinion from European Medicines Agency
Distribution

Moderna receives positive opinion from the EMA for Spikevax

Moderna has revealed the European Medicine's Agency (EMA) has provided positive opinion on its COVID-19 vaccine Spikevax's marketing authorisation
Regulatory

EMA celebrates 25 years of regulatory management

The EMA was founded in January 1995
Regulatory

EMA publishes draft guideline on quality requirements for DDCs

The latest document focuses on combinations of medicinal products and medical devices
Regulatory

GMP inspection in Bulgaria and Cyprus now on par with US

A mutual recognition agreement between the EU and the US regulatory bodies aims to encompass all EU member states, now standing at 24 of the 28
Regulatory

Brexit update: UK Inspection Reports and GMP Certificates

The ECA Academy sheds light on the latest Brexit guidance documents released by the European Medicines Agency
Regulatory

Poland and Slovenia join EU-US mutual recognition agreement for inspections

GMP drug plant inspections conducted by health authorities in Poland and Slovenia will now be accepted by the US FDA
Subscribe now